Category Archives: MS Treatment

Hattiesburg, MS (PRWEB) September 15, 2013 Pine Grove Behavioral Health and Addiction Services announced the new name for their sexual addiction treatment program. After considering more than 200 individual submissions from their alumni and staff, the new program name is Gratitude. Pine Groves Chief Officer, Debbie Sanford, says, The Gratitude program will still provide the same great treatment that we have provided for the past ten years to those suffering from the disease of sexual addiction, sexual anorexia, love and relationship addiction and sexual traumajust under a new name. Gratitude is understood as thankfulness or appreciation and Gratitude is a feeling or attitude that acknowledges the benefit that a patient has received or will receive. The alumni and staff of Pine Grove feel that Gratitude is the appropriate name since hundreds of alumni actively express appreciation for the help they have received. Deborah Schiller, Gratitudes program director, says, It is remarkable to witness our current patients advance from their disease of addiction toward recovery, freedom and gratitude for the healing transformation they begin during treatment at Pine Grove. Pine Groves Gratitude program will still be guided by Deborah Schiller, Program Director, Dr. Jes Montgomery, Psychiatrist and Dr. Gregory Futral, Clinical … Continue reading →

Denver, Colorado (PRWEB) September 13, 2013 According to the Natural Multiple Sclerosis Treatment review on http://www.Sclerosistreatment.com, the new method was developed by a reputed American surgeon, Dr. Gary M. Levin. In fact, Gary Levin also is a researcher who spent several years trying to find a cure for multiple sclerosis (MS). After many attempts, Levin discovered this home remedy that showed a unique efficiency in helping patients of all ages, regardless of the moment when they were first diagnosed. The new method is fully explained with several details by Gary M. Levin in his Natural Multiple Sclerosis Treatment eBook. Interested customers can read the full review at: http://www.sclerosistreatment.com/2013/02/multiple-sclerosis-natural-treatment.html SclerosisTreatment.com writes that here patients will find 100 percent natural remedies that will easily help them enhance overall health. One of the most important things patients should know about this treatment is that it actually is extremely safe. No contraindications, side effects or health concerns are associated to this cure method. According to SclerosisTreatment.com, this natural treatment is absolutely unique due to two important elements. For starters, the treatment targets the cause of this serious condition. Once the cause is eliminated, the treatment focuses on enhancing the immune system. Why is this … Continue reading →

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/tc3kq4/multiple) has announced the addition of the "Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth" report to their offering. Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth Sustained Growth of the Multiple Sclerosis Market The Multiple Sclerosis (MS) market has been growing consistently over the last two decades and is forecast to continue to grow from $8.1 billion in 2012 to $17.6 billion by 2019 at a CAGR of 11.6%. The US will remain the biggest market, constituting approximately 65% of the total by 2019, although this represents little change in the intervening years. Despite some countries in the EU growing more slowly in terms of prevalence than others (such as Germany and Spain), the European market in general will grow due to population growth and subsequent patient-population growth, higher drug prices, and strong uptake due to more expensive and efficacious pipeline drugs. Japan will remain of little significance owing to the very low prevalence population and continued negligible percentage of the overall market, despite high drug prices. The Multiple Sclerosis Therapeutic Landscape is in a State of … Continue reading →

STOCKHOLM--(BUSINESS WIRE)-- Regulatory News: Karo Bio AB (KARO.ST) has been awarded $0,5 million from the National Multiple Sclerosis Society through Fast Forward to develop a novel treatment ERbeta agonists -- for progressive forms of Multiple Sclerosis (MS). The funds will finance the further preclinical development of Karo Bios advanced compounds. Karo Bios ERbeta agonist has the potential to slow disease progression in multiple sclerosis as preclinical models show that it protects neurons and restores myelin. Damaged myelin leads to symptoms of illness and disability in MS patients. This intended profile differs dramatically from currently approved MS therapies, which are used for the treatment of relapsing MS and reduce inflammation, but do not restore myelin or directly protect neurons. We are very pleased to have received this funding from the National MS Society to support our efforts to address important unmet medical needs among MS patients says Per Bengtsson, CEO of Karo Bio. Our aim is to achieve a significant breakthrough in the treatment of MS. This investment by the National MS Society is a continuation of a strategic research focus on gender differences in MS. That effort helped drive basic research into the role of sex hormones, and estrogen in … Continue reading →

Sept. 9, 2013, 11 p.m. IF YOU could bottle Sarah Moncks courage and attitude, you could solve a lot of the worlds problems. The 26-year-old former Ballarat Rush basketballer and assistant coach was diagnosed with Multiple Sclerosis (MS) earlier this year, but shes not letting it beat her. In fact, the diagnosis in May was a relief to the popular basketballer after months of uncertainty. She is a strong believer there are people worse off than she is. Im young and fit and, at the moment, I dont have any symptoms ... so Im lucky, she said. Moncks onset of symptoms was fairly rapid and they hit her hard. In a five-week period late last year, she suffered vision loss, tingling sensation in her mouth, pins and needles down one side of her body, she was unstable on her feet and one side of her face dropped on Christmas Day. On December 27 she was admitted to hospital, where she underwent a series of drugs that greatly eased her symptoms. However, it took another five months before she was diagnosed with lesions on her brain and MS. Continue reading here: Former Ballarat Rush star's battle with MS … Continue reading →

The Saskatchewan government is contemplating its next step after a clinic in the United States cancelled its trial into a controversial treatment for symptoms of multiple sclerosis. The Saskatchewan Party government was informed recently that the Albany Medical Centre is stopping its clinical trial into the effectiveness of angioplasty in treating chronic cerebro-spinal venous insufficiency (CCSVI) and relieving the symptoms of multiple sclerosis (MS). Dr. Gary Siskin, who had been heading up the study, told the Ministry of Health that he was unable to meet the enrolment numbers necessary for the study to produce statistically valid results. Although Saskatchewan had a planned 86 participants, the research team in Albany could not recruit enough participants to meet United States government requirements for a clinical trial. The therapy involves opening blocked veins in the neck. It is not available in Canada and despite some MS patients receiving the therapy overseas, it remains scientifically unproven. Saskatchewan has more people suffering from MS than any province in Canada. The Ministry of Health says it will work with its health and research partners to explore other options. This news is disappointing for the approximately 3,500 Saskatchewan people who want to know whether this kind of … Continue reading →

; Albany researchers cancel MS liberation therapy clinical trial that was using Sask. patients. Supplied / 3D4Medical REGINA A clinical trial to determine the benefits of MS liberation therapy has been cancelled by the researchers. The Albany Medical Clinic informed the Saskatchewan government it is unable to meet the target enrolment necessary for the study to produce statistically valid results. This news is disappointing for the approximately 3,500 Saskatchewan people who want to know whether this kind of treatment can help relieve MS symptoms, said Health Minister Dustin Duncan. MS liberation therapy is a controversial treatment that involves the widening of veins in the neck to improve blood flow to the brain. Some studies have questioned whether the narrowed veins cause MS while proponents of the treatment claim it helps to alleviate the symptoms of MS. Our government wants to do everything it can to search for answers and further the science for people with MS, said Duncan. Thats why Saskatchewan was supportive of this trial and will continue to be supportive of research that may provide answers for those with MS and their families. Saskatchewan had 86 patients planning to take part in the study but the research team … Continue reading →

A clinical trial for the so-called liberation treatment for multiple sclerosis has been cancelled. Saskatchewan had planned to put up $2.2-million to have 86 patients take part in the trial at a medical centre in Albany, N.Y. But the centre has told the province that it wont test the therapy that involves opening blocked neck veins. The trial lead, Dr. Gary Siskin, said they couldnt get enough volunteers for a valid result. Meaning that we needed to have a certain number of patients where, at the end of the trial, wed be able to test the data that we had in a statistically meaningful way and without the right number of patients, those results would be meaningless, Siskin said Monday. Just under 200 people were needed. Siskin said he believes there are two reasons for the lack of volunteers. One is that some physicians question the therapy and didnt push patients to join the trial. The second is that it was a double-blind trial meaning half of those participating would have received liberation therapy and half would get a placebo procedure. The patients would not know which one they got for several years. Its easy to say that everyone would … Continue reading →

CTVNews.ca Staff Published Monday, September 9, 2013 3:41PM EDT Last Updated Monday, September 9, 2013 8:11PM EDT Canadians who were among multiple sclerosis sufferers waiting to take part in a clinical trial into the so-called liberation treatment were disappointed on Monday by news that the trial was cancelled. The Saskatchewan government was told that the Albany Medical Centre in New York has stopped its trial into the effectiveness of angioplasty in treating CCSVI (chronic cerebro-spinal venous insufficiency) and relieving symptoms of multiple sclerosis. The treatment involves opening blocked neck veins. There were 86 planned participants from Saskatchewan -- a province home to one of the highest rates of M.S. sufferers compared to the rest of Canada. The province had committed up to $2.2 million to have its patients participate in the Albany study. Clinical trial lead Dr. Gary Siskin told Saskatchewans Ministry of Health that he wasnt able to meet the overall target enrolment needed for the study to meet U.S. government requirements for a clinical trial. Siskin told CTV News that hes very disappointed the trial had to be cancelled. He spoke about the difficulty in getting people to enrol in the study, as participants seemed reluctant because of … Continue reading →

CTVNews.ca Staff Published Monday, September 9, 2013 3:41PM EDT Last Updated Monday, September 9, 2013 8:11PM EDT Canadians who were among multiple sclerosis sufferers waiting to take part in a clinical trial into the so-called liberation treatment were disappointed on Monday by news that the trial was cancelled. The Saskatchewan government was told that the Albany Medical Centre in New York has stopped its trial into the effectiveness of angioplasty in treating CCSVI (chronic cerebro-spinal venous insufficiency) and relieving symptoms of multiple sclerosis. The treatment involves opening blocked neck veins. There were 86 planned participants from Saskatchewan -- a province home to one of the highest rates of M.S. sufferers compared to the rest of Canada. The province had committed up to $2.2 million to have its patients participate in the Albany study. Clinical trial lead Dr. Gary Siskin told Saskatchewans Ministry of Health that he wasnt able to meet the overall target enrolment needed for the study to meet U.S. government requirements for a clinical trial. Siskin told CTV News that hes very disappointed the trial had to be cancelled. He spoke about the difficulty in getting people to enrol in the study, as participants seemed reluctant because of … Continue reading →